FRESH2 GROUP LIMITED Entry into Material Agreements
On July 28, 2023, Fresh2 Group Limited (the "Company") entered into a Share Purchase Agreement with New-Horizon Bio-Medical Science Co., Ltd. ("New-Horizon"), a Hong Kong company focused on bio-medical technology, under which the Company agreed to sell 100% of the shares of AnPac Bio-Medical Technology (Lishui) Co., Ltd., a subsidiary based in Lishui, China, which has experienced significant financial losses in its operations and is not expected to achieve a breakeven point in the immediate future, to New-Horizon in consideration of RMB1.00. The closing is expected to take place within 30 days from the execution of the agreement.
On July 28, 2023, the Company entered into a Share Purchase Agreement with New-Horizon, under which the Company agreed to sell 100% of the shares of Anpac Technology USA CO., LTD., a subsidiary based in Pennsylvania and California, to New-Horizon in consideration of US$1.00. The closing took place simultaneously with the execution of the agreement.
On July 28, 2023, the Company entered into a Share Purchase Agreement with Ningkasai Technology (Shanghai) Co., Ltd. ("Ningkasai"), a PRC high-tech company specialized in nanotechnologies for life science applications, under which the Company agreed to sell 100% of the shares of Changhe Bio-Medical Technology (Yangzhou) Co., Ltd., a subsidiary based in Yangzhou, China, to Ningkasai in consideration of RMB1.00. The closing is expected to take place within 30 days from the execution of the agreement.
| Exhibit | Description | |
| 10.1 | Share Purchase Agreement dated July 28, 2023 | |
| 10.2 | Share Purchase Agreement dated July 28, 2023 | |
| 10.3 | Share Purchase Agreement dated July 28, 2023 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
AnPac Bio-Medical Science Co. Ltd. published this content on 15 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 August 2023 20:58:05 UTC.
